然后,将全长的配对TCR-αβ链重新导入Jurkat细胞。发现,工程的Jurkat细胞一旦与负载KRAS G12V而不是KRAS WT或G12D肽的PANC-1细胞(表达HLA-A*11:01的胰腺癌细胞株)共同培养时就被激活(图1f;图S5)。这些结果表明,这三个克隆中的T...
图10:k-ras疫苗与阿伐麦布(avasamibe)协同作用以抑制k-ras驱动的肺癌同基因移植肿瘤模型中的肺肿瘤进展。 k-ras驱动的肺癌同基因移植模型中,用k-ras多重肽(multi-peptide)疫苗与阿伐麦布(avasimibe)的组合处理小鼠。肿瘤细胞接种后,评估随时间变化的肿瘤体积。 图11:k-ras疫苗与免疫检查点抑制剂抗-vista协同作用...
Generation of immunity to the HER-2/neu oncogenic protein in patients with breast and ovarian cancer using a peptide-based vaccine. Clin Cancer Res. 1999;5(6):1289–97. CAS PubMed Google Scholar Sallusto F, Lanzavecchia A. Efficient presentation of soluble antigen by cultured human dendritic...
表达区间及表达系统(Source) Biotinylated Human HLA-A*11:01&B2M&KRAS WT (VVGAGGVGK) Monomer Protein is expressed from E.coli with His tag and Avi tag at the C-Terminus. It contains Gly25-Thr305(HLA-A*11:01), Ile21-Met119(B2M) and VVGAGGVGK peptide.[Accession | AAV53343.1(HLA-...
Human KRAS WT(HLA-A*03:01) Tetramer Protein is expressed from HEK293 with His tag and Avi tag at the C-Terminus, tetramer is assembled by biotinylated monomer and streptavidin. It contains Gly25-Thr305(HLA-A*03:01), Ile21-Met119(B2M) and VVVGAGGVGK peptide.[Accession | NP_002107.3...
The affinity of several TCRs was enhanced by phage display, retaining the remarkable ability to distinguish between KRASG12V and KRASWT peptides. In cell-based assays, ImmTAC molecules containing these TCR mediate T cell activation in response to cells expressing KRASG12V but not KRASWT. ...
aOverall X-ray structure of the KRASWTpeptide bound to HLA-A*03:01 (PDB ID 8DVG). β2 microglobulin (β2M) and HLA-A*03:01 are colored in gray and gold, respectively. The 10-mer KRASWT7–16peptide is colored in black. The box highlights the zoomed in region shown in (b).bDet...
KRAS G12C抑制剂 在研机构 浙江劲方药业有限公司[+2] 原研机构 劲方医药科技(上海)有限公司初创企业 在研适应症 KRAS G12C突变非小细胞肺癌[+4] 非在研适应症- 最高研发阶段批准上市 首次获批国家/地区 中国 首次获批日期2024-08-20 Adagrasib
Wild-type KRAS (KRASWT) amplification has been shown to be a secondary means of KRAS activation in cancer and associated with poor survival. Nevertheless, the precise role of KRASWT overexpression in lung cancer progression is largely unexplored. Here, w
evaluated the immunogenicity and safety of KRAS peptide vaccine in 17 tumors with KRAS mutations. Two of the five patients with pancreatic cancer showed proliferative T cell responses, with a longer median survival of 10.5 months [90].